What question did this study set out to answer?

The study aims to assess whether applying human dermal fibroblast exosomes can speed up the re-epithelialization process after deep skin resurfacing.

March 12, 2026

Enhanced Healing and Outcomes With Human Dermal Fibroblast Exosomes: Case Series Combining Deep Helium Radiofrequency Plasma Skin Resurfacing, Facelifts, and Exosomes

Key Points

The study aims to assess whether applying human dermal fibroblast exosomes can speed up the re-epithelialization process after deep skin resurfacing.
Retrospective review of 101 patients
Patients divided into four groups based on treatment type
Comparison of days to full re-epithelialization between groups
Group 1 (no exosomes) re-epithelialization took 10-21 days, median 15.5 days
Group 2 (exosome treated) re-epithelialization took 6-16 days, median 10 days
Significant reduction in re-epithelialization time in exosome groups (P < .0001)
Complications were lower in exosome groups, with Group 4 at 3.03%

Abstract

Abstract Background Deep skin resurfacing with helium radiofrequency plasma produces rhytid and photodamage correction with significant tissue contraction. Although the outcomes can be quite impressive, the recovery process can be daunting and prolonged. Objectives The aim of this study was to demonstrate that topical application of human dermal fibroblast exosomes after deep skin resurfacing can significantly decrease the number of days to achieve re-epithelialization. Methods This study presents a retrospective review (July 2017-September 2025) of 101 patients. The patients were divided into 4 groups: Group 1 (n = 18, resurfacing only, no exosomes, age 36-75 years), Group 2 (n = 27, resurfacing only plus exosomes, age 30-82 years), Group 3 (n = 23, resurfacing plus facelift, no exosomes, age 50-80 years), and Group 4 (n = 33, resurfacing plus facelift, plus exosomes, age 54-77 years). The number of days to full re-epithelialization was compared between groups. Results For the resurfacing-only patients, days to re-epithelialization for Group 1 (no exosomes) ranged from 10 to 21 (median, 15.5; mean standard deviation, 15.78 3.26), compared with Group 2 (exosome treated), which ranged from 6 to 16 days (median, 10; mean, 10.74 2.50) (P .0001 and t-statistic = 5.54). For the resurfacing plus facelift patients, days to re-epithelialization for Group 3 (no exosomes) ranged from 9 to 21 (median, 15; mean, 15.48 3.58), compared with Group 4 (exosome treated), which ranged from 7 to 14 days (median, 10.5; mean 10.24 2.24) (P .0001 and t-statistic = 6.22). The rates of complications were: Group 1, 3 of 18 patients (16.67%); Group 3, 3 of 23 patients (13.04%); Group 2, 0 patients; and Group 4, 1 of 33 patients (3.03%). Conclusions This 8-year series with 101 patients demonstrates that the application of topical exosomes decreased the days to re-epithelialization and the complication rates, highlighting their promising role in accelerated healing following deep skin resurfacing procedures. Level of Evidence: 4

Bookmark

Enhanced Healing and Outcomes With Human Dermal Fibroblast Exosomes: Case Series Combining Deep Helium Radiofrequency Plasma Skin Resurfacing, Facelifts, and Exosomes

Key Points

Abstract

Cite This Study